CHIZF vs JNJ: Which Stock is Better?
Side-by-side comparison of China Traditional Chinese Medicine Holdings Co. Limited and Johnson & Johnson in 2026
CHIZF
China Traditional Chinese Medicine Holdings Co. Limited
$0.27
JNJ
Johnson & Johnson
$230.69
Key Metrics Comparison
| Metric | CHIZF | JNJ | Winner |
|---|---|---|---|
| Market Cap | $1.38B | $564.35B | JNJ |
| P/E Ratio | N/A | 21.23 | JNJ |
| EPS (TTM) | $N/A | $11.03 | JNJ |
| Revenue Growth | -0.1% | 0.1% | JNJ |
| Gross Margin | 48.1% | 68.0% | JNJ |
Analyze CHIZF
Full quant analysis
Analyze JNJ
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHIZF or JNJ a better investment?
Comparing CHIZF and JNJ: China Traditional Chinese Medicine Holdings Co. Limited has a market cap of $1.38B while Johnson & Johnson has $564.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHIZF and JNJ?
CHIZF (China Traditional Chinese Medicine Holdings Co. Limited) and JNJ (Johnson & Johnson) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHIZF or JNJ?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHIZF or JNJ?
JNJ has higher revenue growth at 0.1% vs -0.1% for CHIZF.
Which company is more profitable: CHIZF or JNJ?
Johnson & Johnson (JNJ) has higher gross margins at 68.0% compared to 48.1% for CHIZF.
Which is the larger company: CHIZF or JNJ?
Johnson & Johnson (JNJ) is larger with a market cap of $564.35B compared to $1.38B for CHIZF.
Should I buy CHIZF or JNJ in 2026?
Both CHIZF and JNJ have investment merit. CHIZF trades at $0.27 while JNJ trades at $230.69. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHIZF and JNJ stock?
Key differences: Market Cap ($1.38B vs $564.35B), P/E Ratio (N/A vs 21.2x), Revenue Growth (-0.1% vs 0.1%), Gross Margin (48.1% vs 68.0%).